Difference between revisions of "About-cancer/treatment/clinical-trials/nci-supported"
(Marked this version for translation) |
|||
| Line 1: | Line 1: | ||
<languages/> | <languages/> | ||
<translate> | <translate> | ||
| − | == Selected NCI-Supported Trials == | + | == Selected NCI-Supported Trials == <!--T:1--> |
| + | <!--T:2--> | ||
Find a Clinical Trial | Find a Clinical Trial | ||
| + | <!--T:3--> | ||
Descriptions of some of the major clinical trials that NCI supports to test promising cancer treatments and screening methods. | Descriptions of some of the major clinical trials that NCI supports to test promising cancer treatments and screening methods. | ||
| + | <!--T:4--> | ||
'''Treatment Trials''' | '''Treatment Trials''' | ||
| + | <!--T:5--> | ||
'''NCI-COG Pediatric MATCH''' | '''NCI-COG Pediatric MATCH''' | ||
| + | <!--T:6--> | ||
In this precision medicine clinical trial, children and adolescents with advanced cancers whose tumors have particular genetic mutations are being treated with drugs designed to target those mutations. | In this precision medicine clinical trial, children and adolescents with advanced cancers whose tumors have particular genetic mutations are being treated with drugs designed to target those mutations. | ||
| + | <!--T:7--> | ||
'''NCI-MATCH Trial (Molecular Analysis for Therapy Choice)''' | '''NCI-MATCH Trial (Molecular Analysis for Therapy Choice)''' | ||
| + | <!--T:8--> | ||
Information about the NCI-MATCH precision medicine trial, in which researchers will examine tumor tissue from patients with advanced solid tumors and lymphomas that have stopped responding to treatment and assign patients to treatment arms based on the molecular profiles of their disease. | Information about the NCI-MATCH precision medicine trial, in which researchers will examine tumor tissue from patients with advanced solid tumors and lymphomas that have stopped responding to treatment and assign patients to treatment arms based on the molecular profiles of their disease. | ||
| + | <!--T:9--> | ||
'''The ALCHEMIST Lung Cancer Trials''' | '''The ALCHEMIST Lung Cancer Trials''' | ||
| + | <!--T:10--> | ||
A collection of material about the ALCHEMIST lung cancer trials that will examine tumor tissue from patients with certain types of early-stage, completely resected non-small cell lung cancer for gene mutations in the EGFR and ALK genes, and assign patients with these gene mutations to treatment trials testing post-surgical use of drugs targeted against these mutations. | A collection of material about the ALCHEMIST lung cancer trials that will examine tumor tissue from patients with certain types of early-stage, completely resected non-small cell lung cancer for gene mutations in the EGFR and ALK genes, and assign patients with these gene mutations to treatment trials testing post-surgical use of drugs targeted against these mutations. | ||
| + | <!--T:11--> | ||
'''Lung-MAP: Master Protocol for Lung Cancer''' | '''Lung-MAP: Master Protocol for Lung Cancer''' | ||
| + | <!--T:12--> | ||
The Lung Cancer Master Protocol, or Lung-MAP, is a precision medicine research study for people with advanced non-small cell lung cancer that has continued to grow after treatment. Patients are assigned to different study drug combinations based on the results of genomic profiling of their tumors. | The Lung Cancer Master Protocol, or Lung-MAP, is a precision medicine research study for people with advanced non-small cell lung cancer that has continued to grow after treatment. Patients are assigned to different study drug combinations based on the results of genomic profiling of their tumors. | ||
| + | <!--T:13--> | ||
'''The ALTTO Breast Cancer Trial''' | '''The ALTTO Breast Cancer Trial''' | ||
| + | <!--T:14--> | ||
A collection of material about the Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation, or ALTTO, study that will compare the targeted agents lapatinib and trastuzumab alone, in sequence, or in combination as adjuvant therapy for HER2-positive breast cancer. | A collection of material about the Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation, or ALTTO, study that will compare the targeted agents lapatinib and trastuzumab alone, in sequence, or in combination as adjuvant therapy for HER2-positive breast cancer. | ||
| + | <!--T:15--> | ||
'''The TAILORx Breast Cancer Trial''' | '''The TAILORx Breast Cancer Trial''' | ||
| + | <!--T:16--> | ||
A collection of material about the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, which will examine whether a molecular test can assign women with early-stage breast cancer to the most appropriate and effective treatment. | A collection of material about the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, which will examine whether a molecular test can assign women with early-stage breast cancer to the most appropriate and effective treatment. | ||
| + | <!--T:17--> | ||
'''Testing and Screening Trials''' | '''Testing and Screening Trials''' | ||
| + | <!--T:18--> | ||
'''TMIST (Tomosynthesis Mammographic Imaging Screening Trial)''' | '''TMIST (Tomosynthesis Mammographic Imaging Screening Trial)''' | ||
| + | <!--T:19--> | ||
TMIST is a randomized breast screening trial that compares two Food and Drug Administration (FDA)-approved types of digital mammography, standard digital mammography (2-D) with a newer technology called tomosynthesis mammography (3-D). | TMIST is a randomized breast screening trial that compares two Food and Drug Administration (FDA)-approved types of digital mammography, standard digital mammography (2-D) with a newer technology called tomosynthesis mammography (3-D). | ||
| + | <!--T:20--> | ||
'''National Lung Screening Trial''' | '''National Lung Screening Trial''' | ||
| + | <!--T:21--> | ||
Information about the National Lung Screening Trial (NLST), a research study sponsored by the National Cancer Institute that used low-dose helical CT scans or chest X-ray to screen men and women at risk for lung cancer. | Information about the National Lung Screening Trial (NLST), a research study sponsored by the National Cancer Institute that used low-dose helical CT scans or chest X-ray to screen men and women at risk for lung cancer. | ||
| + | <!--T:22--> | ||
'''Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial''' | '''Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial''' | ||
| + | <!--T:23--> | ||
A large-scale clinical trial to determine whether certain cancer screening tests reduce deaths from prostate, lung, colorectal, and ovarian cancer. In addition, there are numerous epidemiologic and ancillary studies going on that will answer other crucial questions about these cancers and these screening tests. | A large-scale clinical trial to determine whether certain cancer screening tests reduce deaths from prostate, lung, colorectal, and ovarian cancer. In addition, there are numerous epidemiologic and ancillary studies going on that will answer other crucial questions about these cancers and these screening tests. | ||
| + | <!--T:24--> | ||
'''NCI-MATCH Trial (Molecular Analysis for Therapy Choice)''' | '''NCI-MATCH Trial (Molecular Analysis for Therapy Choice)''' | ||
| + | <!--T:25--> | ||
Information about the NCI-MATCH precision medicine trial, in which researchers will examine tumor tissue from patients with advanced solid tumors and lymphomas that have stopped responding to treatment and assign patients to treatment arms based on the molecular profiles of their disease. | Information about the NCI-MATCH precision medicine trial, in which researchers will examine tumor tissue from patients with advanced solid tumors and lymphomas that have stopped responding to treatment and assign patients to treatment arms based on the molecular profiles of their disease. | ||
</translate> | </translate> | ||
Latest revision as of 21:14, 29 October 2019
Selected NCI-Supported Trials
Find a Clinical Trial
Descriptions of some of the major clinical trials that NCI supports to test promising cancer treatments and screening methods.
Treatment Trials
NCI-COG Pediatric MATCH
In this precision medicine clinical trial, children and adolescents with advanced cancers whose tumors have particular genetic mutations are being treated with drugs designed to target those mutations.
NCI-MATCH Trial (Molecular Analysis for Therapy Choice)
Information about the NCI-MATCH precision medicine trial, in which researchers will examine tumor tissue from patients with advanced solid tumors and lymphomas that have stopped responding to treatment and assign patients to treatment arms based on the molecular profiles of their disease.
The ALCHEMIST Lung Cancer Trials
A collection of material about the ALCHEMIST lung cancer trials that will examine tumor tissue from patients with certain types of early-stage, completely resected non-small cell lung cancer for gene mutations in the EGFR and ALK genes, and assign patients with these gene mutations to treatment trials testing post-surgical use of drugs targeted against these mutations.
Lung-MAP: Master Protocol for Lung Cancer
The Lung Cancer Master Protocol, or Lung-MAP, is a precision medicine research study for people with advanced non-small cell lung cancer that has continued to grow after treatment. Patients are assigned to different study drug combinations based on the results of genomic profiling of their tumors.
The ALTTO Breast Cancer Trial
A collection of material about the Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation, or ALTTO, study that will compare the targeted agents lapatinib and trastuzumab alone, in sequence, or in combination as adjuvant therapy for HER2-positive breast cancer.
The TAILORx Breast Cancer Trial
A collection of material about the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, which will examine whether a molecular test can assign women with early-stage breast cancer to the most appropriate and effective treatment.
Testing and Screening Trials
TMIST (Tomosynthesis Mammographic Imaging Screening Trial)
TMIST is a randomized breast screening trial that compares two Food and Drug Administration (FDA)-approved types of digital mammography, standard digital mammography (2-D) with a newer technology called tomosynthesis mammography (3-D).
National Lung Screening Trial
Information about the National Lung Screening Trial (NLST), a research study sponsored by the National Cancer Institute that used low-dose helical CT scans or chest X-ray to screen men and women at risk for lung cancer.
Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial
A large-scale clinical trial to determine whether certain cancer screening tests reduce deaths from prostate, lung, colorectal, and ovarian cancer. In addition, there are numerous epidemiologic and ancillary studies going on that will answer other crucial questions about these cancers and these screening tests.
NCI-MATCH Trial (Molecular Analysis for Therapy Choice)
Information about the NCI-MATCH precision medicine trial, in which researchers will examine tumor tissue from patients with advanced solid tumors and lymphomas that have stopped responding to treatment and assign patients to treatment arms based on the molecular profiles of their disease.
